Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model.

Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron drug with cRGD peptide modification and paclitaxel (PTX) loaded in the hydrophobic core. The nanoparticles (cRGD-COS-CB/PTX) realized the boron delivery into tumor sites with an enhanced permeability and retention (EPR) effect and an active targeting effect achieved by the cRGD-integrin interaction on the surface of tumor cells. The uniform spherical nanoparticles can be selectively taken by hepatoma cells rather than normal hepatocytes. In vivo experiments showed that the nanoparticles had a targeting effect on tumor sites in both subcutaneous and orthotopic tumor models, which was an encouraging result for radiotherapy for liver cancer. To sum up, the nanoparticles we produced proved to be promising dual-functionalized nanoparticles for radiotherapy and chemotherapy.

[1]  D. Su,et al.  MR/NIRF Dual-Mode Imaging of αvβ3 Integrin-Overexpressing Tumors Using a Lipopeptide-Based Contrast Agent. , 2021, Molecular pharmaceutics.

[2]  H. Grossniklaus,et al.  Targeting integrin αvβ3 by a rationally designed protein for chronic liver disease treatment , 2021, Communications Biology.

[3]  Mayya Alexandrovna Dymova,et al.  Boron neutron capture therapy: Current status and future perspectives , 2020, Cancer communications.

[4]  Huimin Shen,et al.  Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma , 2019, Journal of Experimental & Clinical Cancer Research.

[5]  Pengcheng Li,et al.  Advances in chitosan-based nanoparticles for oncotherapy. , 2019, Carbohydrate polymers.

[6]  Z. Lei,et al.  Biomimetic chitosan-graft-polypeptides for improved adhesion in tissue and metal. , 2019, Carbohydrate polymers.

[7]  S. Apisarnthanarax,et al.  Proton Beam Therapy and Carbon Ion Radiotherapy for Hepatocellular Carcinoma. , 2018, Seminars in radiation oncology.

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  S. Miyatake,et al.  Boron Neutron Capture Therapy for High-Grade Skull-Base Meningioma , 2018, Journal of Neurological Surgery Part B: Skull Base.

[10]  P. Mi,et al.  Boron delivery agents for neutron capture therapy of cancer , 2018, Cancer communications.

[11]  K. Ono,et al.  Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget’s disease with curative responses , 2018, Cancer communications.

[12]  D. Brigstock,et al.  Pathways of production and delivery of hepatocyte exosomes , 2018, Journal of Cell Communication and Signaling.

[13]  Zhanyong Guo,et al.  Synthesis, characterization, and the antifungal activity of chitosan derivatives containing urea groups. , 2017, International journal of biological macromolecules.

[14]  V. Chatsudthipong,et al.  Chitosan oligosaccharide: Biological activities and potential therapeutic applications , 2017, Pharmacology & therapeutics.

[15]  Xing-Xing He,et al.  Mouse models of liver cancer: Progress and recommendations , 2015, Oncotarget.

[16]  B. Weaver,et al.  How Taxol/paclitaxel kills cancer cells , 2014, Molecular biology of the cell.

[17]  K. Ono,et al.  BNCT for advanced or recurrent head and neck cancer. , 2014, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[18]  D. Yardley nab-Paclitaxel mechanisms of action and delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Jaroslav Turánek,et al.  Liposomal paclitaxel formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[20]  M. Garcia‐Fuentes,et al.  Chitosan-based drug nanocarriers: where do we stand? , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[21]  T. Park,et al.  RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[22]  M. Makuuchi,et al.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.

[23]  L. Salford,et al.  Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[25]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[26]  T. Kageji,et al.  Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: comparison of clinical results obtained with BNCT and conventional treatment. , 2014, The journal of medical investigation : JMI.